{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:47:13Z","timestamp":1790660833408,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,28]],"date-time":"2011-01-28T00:00:00Z","timestamp":1296172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s11940-011-0113-1","type":"journal-article","created":{"date-parts":[[2011,1,26]],"date-time":"2011-01-26T23:07:06Z","timestamp":1296083226000},"page":"143-159","source":"Crossref","is-referenced-by-count":71,"title":["Treatment of Diabetic Sensory Polyneuropathy"],"prefix":"10.1007","volume":"13","author":[{"given":"Lindsay","family":"Zilliox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,28]]},"reference":[{"key":"113_CR1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2004","unstructured":"Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diab Care 2004, 27:1047\u20131053.","journal-title":"Diab Care"},{"key":"113_CR2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/archinte.158.2.134","volume":"158","author":"B Gaster","year":"1998","unstructured":"Gaster B, Hirsch IB: The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998, 158:134\u2013140.","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"113_CR3","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.2337\/dc08-s263","volume":"31","author":"D Ziegler","year":"2008","unstructured":"Ziegler D: Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diab Care 2008, 31(Suppl 2):S255\u201361.","journal-title":"Diab Care"},{"key":"113_CR4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF00399096","volume":"36","author":"JM Lehtinen","year":"1993","unstructured":"Lehtinen JM, Niskanen L, Hyvonen K, Siitonen O, Uusitupa M: Nerve function and its determinants in patients with newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus and in control subjects\u2013a 5-year follow-up. Diabetologia 1993, 36:68\u201372.","journal-title":"Diabetologia"},{"key":"113_CR5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-4598(199801)21:1<72::AID-MUS10>3.0.CO;2-2","volume":"21","author":"JA Cohen","year":"1998","unstructured":"Cohen JA, Jeffers BW, Faldut D, Marcoux M, Schrier RW: Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). Muscle Nerve 1998, 21:72\u201380.","journal-title":"Muscle Nerve"},{"key":"113_CR6","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.2337\/dc07-0850","volume":"30","author":"JW Albers","year":"2007","unstructured":"Albers JW, Herman WH, Pop-Busui R, et al.: Subclinical neuropathy among diabetes control and complications trial participants without diagnosable neuropathy at trial completion: Possible predictors of incident neuropathy? Diab Care 2007, 30:2613\u20132618.","journal-title":"Diab Care"},{"key":"113_CR7","doi-asserted-by":"crossref","unstructured":"Executive summary: Standards of medical care in diabetes--2010. Diab Care 2010, 33 Suppl 1:S4-10.","DOI":"10.2337\/dc10-S004"},{"issue":"Suppl 1","key":"113_CR8","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc10-S011","volume":"33","author":"American Diabetes Association","year":"2010","unstructured":"American Diabetes Association: Standards of medical care in diabetes--2010. Diab Care 2010, 33(Suppl 1):S11\u201361.","journal-title":"Diab Care"},{"key":"113_CR9","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2337\/diacare.24.8.1448","volume":"24","author":"JR Singleton","year":"2001","unstructured":"Singleton JR, Smith AG, Bromberg MB: Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diab Care 2001, 24:1448\u20131453.","journal-title":"Diab Care"},{"key":"113_CR10","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2337\/dc06-0224","volume":"29","author":"AG Smith","year":"2006","unstructured":"Smith AG, Russell J, Feldman EL, et al.: Lifestyle intervention for pre-diabetic neuropathy. Diab Care 2006, 29:1294\u20131299.","journal-title":"Diab Care"},{"key":"113_CR11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11906-004-0084-7","volume":"6","author":"HA Punzi","year":"2004","unstructured":"Punzi HA, Punzi CF: Antihypertensive and lipid-lowering heart attack trial study, trinity hypertension research institute: metabolic issues in the antihypertensive and lipid-lowering heart attack trial study. Curr Hypertens Rep 2004, 6:106\u2013110.","journal-title":"Curr Hypertens Rep"},{"key":"113_CR12","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","volume":"362","author":"JJ McMurray","year":"2010","unstructured":"NAVIGATOR Study Group, McMurray JJ, Holman RR, et al.: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1477\u20131490.","journal-title":"N Engl J Med"},{"key":"113_CR13","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/S0140-6736(98)02478-7","volume":"352","author":"RA Malik","year":"1998","unstructured":"Malik RA, Williamson S, Abbott C, et al.: Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998, 352:1978\u20131981.","journal-title":"Lancet"},{"key":"113_CR14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ejphar.2010.10.047","volume":"650","author":"CL Oltman","year":"2011","unstructured":"Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Dake B, Yorek MA: Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats. Eur J Pharmacol 2011, 650:556\u201362.","journal-title":"Eur J Pharmacol"},{"key":"113_CR15","doi-asserted-by":"crossref","unstructured":"The effect of intensive diabetes therapy on the development and progression of neuropathy. the diabetes control and complications trial research group. Ann Intern Med 1995, 122:561\u2013568.","DOI":"10.7326\/0003-4819-122-8-199504150-00001"},{"key":"113_CR16","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet 1998, 352:837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"113_CR17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","volume":"353","author":"P Gaede","year":"1999","unstructured":"Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the steno type 2 randomised study. Lancet 1999, 353:617\u2013622.","journal-title":"Lancet"},{"key":"113_CR18","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/dc09-1941","volume":"33","author":"JW Albers","year":"2010","unstructured":"Albers JW, Herman WH, Pop-Busui R, et al.: Effect of prior intensive insulin treatment during the diabetes control and complications trial (DCCT) on peripheral neuropathy in type 1 diabetes during the epidemiology of diabetes interventions and complications (EDIC) study. Diab Care 2010, 33:1090\u20131096.","journal-title":"Diab Care"},{"key":"113_CR19","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1161\/CIRCULATIONAHA.108.837369","volume":"119","author":"R Pop-Busui","year":"2009","unstructured":"Pop-Busui R, Low PA, Waberski BH, et al.: Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the diabetes control and complications Trial\/Epidemiology of diabetes interventions and complications study (DCCT\/EDIC). Circulation 2009, 119:2886\u20132893.","journal-title":"Circulation"},{"key":"113_CR20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393\u2013403.","journal-title":"N Engl J Med"},{"key":"113_CR21","first-page":"849","volume-title":"Neurobiology of disease","author":"JW Russell","year":"2006","unstructured":"Russell JW, Smith AG, Singleton JR: Impaired glucose regulation and neuropathy. In Neurobiology of disease. By Gilman S. San Diego: Elsevier; 2006:849\u2013869."},{"key":"113_CR22","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2337\/diabetes.52.12.2867","volume":"52","author":"JR Singleton","year":"2003","unstructured":"Singleton JR, Smith AG, Russell JW, Feldman EL: Microvascular complications of impaired glucose tolerance. Diabetes 2003, 52:2867\u20132873.","journal-title":"Diabetes"},{"key":"113_CR23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10715769900300721","volume":"31","author":"M Reljanovic","year":"1999","unstructured":"Reljanovic M, Reichel G, Rett K, et al.: Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a 2\u00a0year multicenter randomized double-blind placebo-controlled trial (ALADIN II). alpha lipoic acid in diabetic neuropathy. Free Radic Res 1999, 31:171\u2013179.","journal-title":"Free Radic Res"},{"key":"113_CR24","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.2337\/diacare.22.8.1296","volume":"22","author":"D Ziegler","year":"1999","unstructured":"Ziegler D, Hanefeld M, Ruhnau KJ, et al.: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). ALADIN III study group. alpha-lipoic acid in diabetic neuropathy. Diab Care 1999, 22:1296\u20131301.","journal-title":"Diab Care"},{"key":"113_CR25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/diacare.20.3.369","volume":"20","author":"D Ziegler","year":"1997","unstructured":"Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G: Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN study). Deutsche kardiale autonome neuropathie. Diab Care 1997, 20:369\u2013373.","journal-title":"Diab Care"},{"key":"113_CR26","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2337\/dc06-1216","volume":"29","author":"D Ziegler","year":"2006","unstructured":"Ziegler D, Ametov A, Barinov A, et al.: Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diab Care 2006, 29:2365\u20132370.","journal-title":"Diab Care"},{"key":"113_CR27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1464-5491.2004.01109.x","volume":"21","author":"D Ziegler","year":"2004","unstructured":"Ziegler D, Nowak H, Kempler P, Vargha P, Low PA: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004, 21:114\u2013121.","journal-title":"Diabet Med"},{"key":"113_CR28","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/mus.1136","volume":"24","author":"JR Singleton","year":"2001","unstructured":"Singleton JR, Smith AG, Bromberg MB: Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001, 24:1225\u20131228.","journal-title":"Muscle Nerve"},{"issue":"Suppl 2","key":"113_CR29","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.2337\/dc09-S350","volume":"32","author":"D Ziegler","year":"2009","unstructured":"Ziegler D: Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diab Care 2009, 32(Suppl 2):S414\u20139.","journal-title":"Diab Care"},{"key":"113_CR30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1212\/WNL.0b013e3181c918fc","volume":"74","author":"RM Dubinsky","year":"2010","unstructured":"Dubinsky RM, Miyasaki J: Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2010, 74:173\u2013176.","journal-title":"Neurology"},{"key":"113_CR31","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","volume":"280","author":"M Backonja","year":"1998","unstructured":"Backonja M, Beydoun A, Edwards KR, et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998, 280:1831\u20131836.","journal-title":"JAMA"},{"key":"113_CR32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/jnnp.66.2.251","volume":"66","author":"KC Gorson","year":"1999","unstructured":"Gorson KC, Schott C, Herman R, Ropper AH, Rand WM: Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999, 66:251\u2013252.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"113_CR33","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","volume":"63","author":"H Lesser","year":"2004","unstructured":"Lesser H, Sharma U, LaMoreaux L, Poole RM: Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004, 63:2104\u20132110.","journal-title":"Neurology"},{"key":"113_CR34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","volume":"110","author":"J Rosenstock","year":"2004","unstructured":"Rosenstock J, Tuchman M, LaMoreaux L, Sharma U: Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004, 110:628\u2013638.","journal-title":"Pain"},{"key":"113_CR35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","volume":"6","author":"RW Richter","year":"2005","unstructured":"Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE: Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005, 6:253\u2013260.","journal-title":"J Pain"},{"key":"113_CR36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","volume":"115","author":"R Freynhagen","year":"2005","unstructured":"Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M: Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005, 115:254\u2013263.","journal-title":"Pain"},{"key":"113_CR37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1034\/j.1600-0404.2002.01229.x","volume":"106","author":"DK Kochar","year":"2002","unstructured":"Kochar DK, Jain N, Agarwal RP, Srivastava T, Agarwal P, Gupta S: Sodium valproate in the management of painful neuropathy in type 2 diabetes\u2014a randomized placebo controlled study. Acta Neurol Scand 2002, 106:248\u2013252.","journal-title":"Acta Neurol Scand"},{"key":"113_CR38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/qjmed\/hch007","volume":"97","author":"DK Kochar","year":"2004","unstructured":"Kochar DK, Rawat N, Agrawal RP, et al.: Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004, 97:33\u201338.","journal-title":"QJM"},{"key":"113_CR39","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/01.WNL.0000137341.89781.14","volume":"63","author":"P Raskin","year":"2004","unstructured":"Raskin P, Donofrio PD, Rosenthal NR, et al.: Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004, 63:865\u2013873.","journal-title":"Neurology"},{"key":"113_CR40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.pain.2004.05.010","volume":"110","author":"MC Rowbotham","year":"2004","unstructured":"Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004, 110:697\u2013706.","journal-title":"Pain"},{"key":"113_CR41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00131402-200112000-00002","volume":"3","author":"DA Simpson","year":"2001","unstructured":"Simpson DA: Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis 2001, 3:53\u201362.","journal-title":"J Clin Neuromuscul Dis"},{"key":"113_CR42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","volume":"6","author":"J Raskin","year":"2005","unstructured":"Raskin J, Pritchett YL, Wang F, et al.: A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005, 6:346\u2013356.","journal-title":"Pain Med"},{"key":"113_CR43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","volume":"116","author":"DJ Goldstein","year":"2005","unstructured":"Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005, 116:109\u2013118.","journal-title":"Pain"},{"key":"113_CR44","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","volume":"67","author":"JF Wernicke","year":"2006","unstructured":"Wernicke JF, Pritchett YL, D\u2019Souza DN, et al.: A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006, 67:1411\u20131420.","journal-title":"Neurology"},{"key":"113_CR45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/jpet.104.070656","volume":"311","author":"S Iyengar","year":"2004","unstructured":"Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM: Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004, 311:576\u2013584.","journal-title":"J Pharmacol Exp Ther"},{"key":"113_CR46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00002508-199712000-00009","volume":"13","author":"M Vrethem","year":"1997","unstructured":"Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindstrom T, Thorell LH: A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 1997, 13:313\u2013323.","journal-title":"Clin J Pain"},{"key":"113_CR47","first-page":"123","volume":"34","author":"MB Max","year":"1987","unstructured":"Max MB: Endogenous monoamine analgesic systems: amitriptyline in painful diabetic neuropathy. Anesth Prog 1987, 34:123\u2013127.","journal-title":"Anesth Prog"},{"key":"113_CR48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.37.4.589","volume":"37","author":"MB Max","year":"1987","unstructured":"Max MB, Culnane M, Schafer SC, et al.: Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987, 37:589\u2013596.","journal-title":"Neurology"},{"key":"113_CR49","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1001\/jama.251.13.1727","volume":"251","author":"B Kvinesdal","year":"1984","unstructured":"Kvinesdal B, Molin J, Froland A, Gram LF: Imipramine treatment of painful diabetic neuropathy. JAMA 1984, 251:1727\u20131730.","journal-title":"JAMA"},{"key":"113_CR50","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0304-3959(85)90010-7","volume":"23","author":"FJ Gomez-Perez","year":"1985","unstructured":"Gomez-Perez FJ, Rull JA, Dies H, Rodriquez-Rivera JG, Gonzalez-Barranco J, Lozano-Castaneda O: Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain 1985, 23:395\u2013400.","journal-title":"Pain"},{"key":"113_CR51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0304-3959(99)00079-2","volume":"83","author":"SH Sindrup","year":"1999","unstructured":"Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS: Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999, 83:85\u201390.","journal-title":"Pain"},{"key":"113_CR52","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2044.1992.tb03253.x","volume":"47","author":"HJ McQuay","year":"1992","unstructured":"McQuay HJ, Jadad AR, Carroll D, et al.: Opioid sensitivity of chronic pain: a patient-controlled analgesia method. Anaesthesia 1992, 47:757\u2013767.","journal-title":"Anaesthesia"},{"key":"113_CR53","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa042580","volume":"352","author":"I Gilron","year":"2005","unstructured":"Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005, 352:1324\u20131334.","journal-title":"N Engl J Med"},{"key":"113_CR54","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1212\/WNL.50.6.1842","volume":"50","author":"Y Harati","year":"1998","unstructured":"Harati Y, Gooch C, Swenson M, et al.: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998, 50:1842\u20131846.","journal-title":"Neurology"},{"key":"113_CR55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1185\/030079906X162674","volume":"23","author":"R Freeman","year":"2007","unstructured":"Freeman R, Raskin P, Hewitt DJ, et al.: Randomized study of tramadol\/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin 2007, 23:147\u2013161.","journal-title":"Curr Med Res Opin"},{"key":"113_CR56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0304-3959(90)91110-5","volume":"41","author":"B Lynn","year":"1990","unstructured":"Lynn B: Capsaicin: actions on nociceptive C-fibres and therapeutic potential. Pain 1990, 41:61\u201369.","journal-title":"Pain"},{"key":"113_CR57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2337\/diacare.15.1.8","volume":"15","author":"R Tandan","year":"1992","unstructured":"Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ: Topical capsaicin in painful diabetic neuropathy. controlled study with long-term follow-up. Diab Care 1992, 15:8\u201314.","journal-title":"Diab Care"},{"key":"113_CR58","doi-asserted-by":"crossref","unstructured":"Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. the capsaicin study group. Arch Intern Med 1991, 151:2225\u20132229.","DOI":"10.1001\/archinte.151.11.2225"},{"issue":"Suppl 2","key":"113_CR59","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1185\/030079904X12960","volume":"20","author":"CE Argoff","year":"2004","unstructured":"Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR: Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the neuropathic pain scale. Curr Med Res Opin 2004, 20(Suppl 2):S21\u20138.","journal-title":"Curr Med Res Opin"},{"key":"113_CR60","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archneur.61.6.914","volume":"61","author":"RL Barbano","year":"2004","unstructured":"Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH: Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004, 61:914\u2013918.","journal-title":"Arch Neurol"},{"key":"113_CR61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0891-5849(01)00564-0","volume":"31","author":"NE Cameron","year":"2001","unstructured":"Cameron NE, Jack AM, Cotter MA: Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001, 31:125\u2013135.","journal-title":"Free Radic Biol Med"},{"key":"113_CR62","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/BF00400603","volume":"38","author":"D Ziegler","year":"1995","unstructured":"Ziegler D, Hanefeld M, Ruhnau KJ, et al.: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study). Diabetologia 1995, 38:1425\u20131433.","journal-title":"Diabetologia"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0113-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-011-0113-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0113-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T00:24:18Z","timestamp":1559953458000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-011-0113-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,28]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["113"],"URL":"https:\/\/doi.org\/10.1007\/s11940-011-0113-1","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,28]]}}}